CA2208916A1 - Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels - Google Patents

Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels

Info

Publication number
CA2208916A1
CA2208916A1 CA002208916A CA2208916A CA2208916A1 CA 2208916 A1 CA2208916 A1 CA 2208916A1 CA 002208916 A CA002208916 A CA 002208916A CA 2208916 A CA2208916 A CA 2208916A CA 2208916 A1 CA2208916 A1 CA 2208916A1
Authority
CA
Canada
Prior art keywords
steroids
composition
dione
tetrahydrocortisol
tetrahydrocortisone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002208916A
Other languages
English (en)
Inventor
Michael P. Seed
Chandan Alam
Derek A. Willoughby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Hyal Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp
Priority to CA002208916A priority Critical patent/CA2208916A1/fr
Priority to AU82021/98A priority patent/AU8202198A/en
Priority to PCT/CA1998/000649 priority patent/WO1999001142A1/fr
Publication of CA2208916A1 publication Critical patent/CA2208916A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002208916A 1997-07-03 1997-07-03 Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels Abandoned CA2208916A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002208916A CA2208916A1 (fr) 1997-07-03 1997-07-03 Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels
AU82021/98A AU8202198A (en) 1997-07-03 1998-07-03 Pharmaceutical compositions comprising an angiostatic steroid combined with a hyaluronan
PCT/CA1998/000649 WO1999001142A1 (fr) 1997-07-03 1998-07-03 Compositions pharmaceutiques comprenant un steroide angiostatique combine a un hyaluronan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002208916A CA2208916A1 (fr) 1997-07-03 1997-07-03 Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels

Publications (1)

Publication Number Publication Date
CA2208916A1 true CA2208916A1 (fr) 1999-01-03

Family

ID=4160953

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002208916A Abandoned CA2208916A1 (fr) 1997-07-03 1997-07-03 Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels

Country Status (3)

Country Link
AU (1) AU8202198A (fr)
CA (1) CA2208916A1 (fr)
WO (1) WO1999001142A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
JP2004537499A (ja) * 2000-11-27 2004-12-16 エントレメッド インコーポレイテッド 抗血管新生薬
CA2558014A1 (fr) 2004-03-12 2005-09-29 Entremed, Inc. Agents anti-angiogeniques
US8399440B2 (en) 2006-03-20 2013-03-19 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
FR2918892B1 (fr) * 2007-07-16 2010-02-12 Fabre Pierre Dermo Cosmetique Composition dermatologique anti-inflammatoire comprenant des corticoides et des fragments de hyaluronate, et ses utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
JPH04506066A (ja) * 1989-06-16 1992-10-22 ジ・アップジョン・カンパニー 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類

Also Published As

Publication number Publication date
AU8202198A (en) 1999-01-25
WO1999001142A1 (fr) 1999-01-14

Similar Documents

Publication Publication Date Title
US5529987A (en) Hyaluronic acid-urea pharmaceutical compositions and uses
US5166331A (en) Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
Bhatia et al. Topical phenytoin for wound healing
FI79554B (fi) Foerfarande foer framstaellning av hyaluronsyrafraktioner med farmaceutisk aktivitet.
AU732344B2 (en) Oral administration of effective amounts of forms of hyaluronic acid
EP0716596B1 (fr) Nouvelles compositions pharmaceutiques a usage topique renfermant de l'acide hyaluronique et ses derives
HU220758B1 (hu) Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
JP4234198B2 (ja) 獣医学および医学用途用化合物
KR20080031394A (ko) Ｔｇｆ-베타 수퍼패밀리 구성원을 포함하는 약학 조성물
JPH09512797A (ja) 癌の治療および転移の予防
US5550112A (en) Hyaluronic acid-urea pharmaceutical compositions and uses
CA2208916A1 (fr) Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels
AU694113B2 (en) Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
EP0988040B1 (fr) Utilisation de glucosamine et de derives de glucosamine pour le soulagement rapide de prurit ou de douleurs localisees
WO1994015623A9 (fr) Compositions pharmaceutiques a base d'acide hyaluronique et d'uree, et leurs utilisations
US6596703B1 (en) Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
KR20010021852A (ko) 항통각과민성 아편제의 필름 형성 조성물 및 이것으로통각과민증 및 소양증을 치료하는 방법
IL96711A (en) Insulin-like growth factor for the treatment of adverse effects of steroid laxity
US20050187185A1 (en) Pharmaceutical applications of hyaluronic acid preparations
AP619A (en) Use of hyaluronic acid or salt for the treatment of a human having a stroke or myocardial infarction.
EP0365613B1 (fr) Tobramycine et steroides combines destines a une utilisation ophtalmique topique
RU2528905C1 (ru) Способ лечения ран мягких тканей различной этиологии
RU2223097C1 (ru) Комбинированное средство для лечения кожных заболеваний
JPH04208219A (ja) 褥瘡及び皮膚潰瘍治療外用剤
JPH11209291A (ja) 痔疾治療剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead